Y. Lu

Regeneron Pharmaceuticals, Inc.

Poster Author Of 5 e-Posters

 ePosters
03. Asthma

A2666 - Dupilumab Improved Asthma Control and Health-Related Quality of Life in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study

Presenter:
Date
05/20/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
B21 - SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
03. Asthma

A2667 - Dupilumab Reduces Severe Exacerbations and Improves Lung Function in Late-Onset, Uncontrolled, Moderate-to-Severe Asthma Patients Enrolled in the LIBERTY ASTHMA QUEST Study

Presenter:
Date
05/20/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
B21 - SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
03. Asthma

A2668 - Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma Despite Exacerbation Events During the LIBERTY ASTHMA QUEST Study

Presenter:
Date
05/20/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
B21 - SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
03. Asthma

A2669 - Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study

Presenter:
Date
05/20/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
B21 - SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
03. Asthma

A7086 - Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma

Presenter:
Date
05/22/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
D101 - CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors